1. Home
  2. CSWC vs HROW Comparison

CSWC vs HROW Comparison

Compare CSWC & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capital Southwest Corporation

CSWC

Capital Southwest Corporation

HOLD

Current Price

$23.83

Market Cap

1.4B

ML Signal

HOLD

Logo Harrow Inc.

HROW

Harrow Inc.

HOLD

Current Price

$42.31

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSWC
HROW
Founded
1961
1998
Country
United States
United States
Employees
36
373
Industry
Textiles
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.4B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CSWC
HROW
Price
$23.83
$42.31
Analyst Decision
Buy
Strong Buy
Analyst Count
5
8
Target Price
$23.50
$69.86
AVG Volume (30 Days)
648.6K
836.4K
Earning Date
05-13-2026
05-11-2026
Dividend Yield
10.89%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$17.45
$31.62
Revenue Next Year
$10.26
$50.77
P/E Ratio
$12.65
N/A
Revenue Growth
N/A
N/A
52 Week Low
$19.37
$28.54
52 Week High
$24.43
$54.98

Technical Indicators

Market Signals
Indicator
CSWC
HROW
Relative Strength Index (RSI) 55.96 62.69
Support Level $22.76 $40.61
Resistance Level $23.79 $44.50
Average True Range (ATR) 0.37 2.09
MACD 0.09 0.21
Stochastic Oscillator 73.80 64.70

Price Performance

Historical Comparison
CSWC
HROW

About CSWC Capital Southwest Corporation

Capital Southwest Corp is a U.S.-based investment company that specializes in providing customized financing to middle market companies across various industries. The company's investment objective is to produce attractive risk-adjusted returns by generating current income from debt investments and capital appreciation from equity and equity related investments. It focuses on providing flexible financing solutions through partnerships with business owners, management teams, and financial sponsors. The company's portfolio may include senior debt, second lien, and subordinated debt, preferred stocks, common stocks, and warrants. The primary source of revenue comprises interest income and dividend income from investments made as well as management fees.

About HROW Harrow Inc.

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

Share on Social Networks: